Claritev (CTEV) Q4 2024 earnings summary

Executive summary

• Completed a major rebranding to Claritev, launching Vision 2030 and positioning as a health technology leader focused on affordability, transparency, and quality in healthcare.

• Assembled a new executive leadership team, including a Chief AI Officer and Chief Growth Officer, to drive innovation and growth.

• Closed a $34 million contract, renewed a top client for three years, and received multiple industry awards.

• Successfully refinanced $4.56 billion in debt in Q1 2025, extending maturities by three years with 99.75% participation.

• Recorded a $1.49 billion impairment of goodwill and intangible assets, resulting in a net loss surge for 2024.

Financial highlights

• FY 2024 revenue was $930.6 million, down 3.2% year-over-year; Q4 2024 revenue was $232.1 million, down 4.9% year-over-year.

• Adjusted EBITDA for FY 2024 was $576.7 million, down 6.7%, with a margin of 62%.

• Operating cash flow for FY 2024 was $107.6 million; free cash flow was $(10.5) million.

• Network-based revenues declined 17.1%, analytics-based revenues increased 1.4%, and payment/revenue integrity revenues decreased 1.6% year-over-year.

• Processed $177.6 billion in medical charges and identified $24.7 billion in potential cost savings, up 7.5% year-over-year.

Outlook and guidance

• FY 2025 revenue guidance is flat to down 2% versus 2024, with sequential quarterly growth expected.

• Adjusted EBITDA margin guidance for 2025 is 62.5%-63.5%.

• Capital expenditures projected at $155 million-$165 million; free cash flow guidance is $(65) million to $(75) million.

• Net revenue retention in core segments forecasted at 97%; double-digit growth expected in HST and Data & Decision Science segments.

• Long-term target is mid- to high-single-digit revenue growth and a Rule of 70 (EBITDA margin plus revenue growth).